Nancy E. Stagliano
Vorstandsvorsitzender bei Neuron23, Inc.
Profil
Nancy E.
Stagliano is the founder of CytomX Therapeutics, Inc. (founded in 2008) and True North Therapeutics, Inc. (founded in 2013).
She held the title of Chief Executive Officer & Director at True North Therapeutics, Inc. from 2013 to 2017.
Dr. Stagliano is also the founder of CytomX Therapeutics Holdings LLC.
Dr. Stagliano's current job(s) include being the Chairman & Co-Chief Executive Officer at Neuron23, Inc. since 2019, the Executive Chairman at Electra Therapeutics, Inc., the Chairman at Star Therapeutics, Inc. since 2018, a Director at Pancreatic Cancer Action Network, Inc. since 2020, and an Independent Director at Pandion Operations, Inc. since 2018.
Dr. Stagliano's former job(s) include being the Chief Executive Officer & Director at iPierian, Inc. from 2011 to 2014, an Associate Director-Discovery Strategy at Millennium Pharmaceuticals, Inc., an Independent Director at biOasis Technologies, Inc. from 2017 to 2019, and an Independent Director at Pandion Therapeutics, Inc. She also held the position of Chief Operating Officer & VP-Development at CytomX LLC.
Dr. Stagliano's education includes undergraduate and graduate degrees from Drexel University and a doctorate degree from the University of Miami.
Aktive Positionen von Nancy E. Stagliano
| Unternehmen | Position | Beginn |
|---|---|---|
Pandion Operations, Inc.
 Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 26.07.2018 |
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Vorstandsvorsitzender | - |
Pancreatic Cancer Action Network, Inc.
 Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Pancreatic Cancer Action Network, Inc. engages in the research, clinical initiatives, patient services, and advocacy for pancreatic cancer. The company was founded in 1999 and is headquartered in Manhattan Beach, CA. | Direktor/Vorstandsmitglied | 04.08.2020 |
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Vorsitzender | 01.06.2018 |
Electra Therapeutics, Inc.
 Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Vorsitzender | - |
Ehemalige bekannte Positionen von Nancy E. Stagliano
| Unternehmen | Position | Ende |
|---|---|---|
| PANDION THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2021 |
| BIOASIS TECHNOLOGIES INC. | Direktor/Vorstandsmitglied | 25.11.2019 |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Gründer | 01.06.2017 |
iPierian, Inc.
 iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Vorstandsvorsitzender | 01.04.2014 |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Nancy E. Stagliano
| Drexel University | Graduate Degree |
| University of Miami | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
CytomX LLC
 CytomX LLC Medical SpecialtiesHealth Technology CytomX LLC develops protein therapeutics and integrated medical diagnostic devices. It provides molecular engineering and micro fluidic cell separation technologies. The company was co-founded by Dr. Hyongsok Soh, Dr. Alan J. Heeger, and Dr. Patrick S. Daugherty in 2006 and is headquartered in Santa Barbara, CA | Health Technology |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Health Technology |
iPierian, Inc.
iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Pancreatic Cancer Action Network, Inc.
Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Pancreatic Cancer Action Network, Inc. engages in the research, clinical initiatives, patient services, and advocacy for pancreatic cancer. The company was founded in 1999 and is headquartered in Manhattan Beach, CA. | Health Services |
Pandion Operations, Inc.
Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Commercial Services |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
Electra Therapeutics, Inc.
Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
